SCHEMBL17679253

SCHEMBL17679253

Cc1ccc([C@H]2COc3cc(O)ccc3C2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 6/20 0.83
ESR1 P03372 5/20 0.83
TTR P02766 1/20 0.83
ALOX15 P16050 7/20 0.62
ALOX12 P18054 6/20 0.62
ALOX15B O15296 3/20 0.62
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
THRB P10828 1/20 0.46
KMT2A Q03164 1/20 0.46
RARA P10276 1/20 0.44
RARB P10826 1/20 0.44
RARG P13631 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GLA P06280 1/20 0.43
HPGD P15428 1/20 0.43
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19861143 1.00 ESR2 (0.83) ESR2ESR1TTRALOX15ALOX12
SCHEMBL31545730 1.00 ESR2 (0.83) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL29005767 0.92 ESR2 (0.79) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL29005768 0.92 ESR2 (0.79) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL29005752 0.92 ESR2 (0.79) ESR2ESR1TTRALOX15ALOX12
SCHEMBL17565590 0.91 ESR2 (0.78) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL677723 0.91 ESR2 (1.00) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL43648 0.91 ESR2 (1.00) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL29467332 0.91 ESR2 (1.00) ESR2ESR1TTRALOX15ALOX12
Aus-131 SCHEMBL2002128 0.91 ESR2 (1.00) ESR2ESR1TTRALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-9914718-B2 Anhydrous crystalline form of S-equol AUSIO PHARMACEUTICALS, LLC (US) 2018-03-13 US disclosed
US-20160102070-A1 ANHYDROUS CRYSTALLINE FORM OF S-EQUOL AUSIO PHARMACEUTICALS, LLC (US) 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102070-A1 ANHYDROUS CRYSTALLINE FORM OF S-EQUOL SULT2A1, SULT1E1, SULT1A1 ESR2 157/4885ESR1 94/4885TTR 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.